These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36419889)

  • 1. Case report:
    Lazzari C; Pecciarini L; Doglioni C; Pedica F; Gajate AMS; Bulotta A; Gregorc V; Cangi MG
    Front Oncol; 2022; 12():1038774. PubMed ID: 36419889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
    Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
    Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel EML4-NTRK3 fusion in lung adenocarcinoma with dramatic response to entrectinib.
    Batra U; Nathany S; Sharma M; Jain P; Mehta A; Bansal A
    J Cancer Res Ther; 2023 Oct; 19(7):2045-2047. PubMed ID: 38376315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
    Gao L; Ai X; Lu S
    Lung Cancer; 2024 Jan; 187():107443. PubMed ID: 38113652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report.
    Palmerini E; Frega G; Gambarotti M; Frisoni T; Cesari M; Bazzocchi A; Miceli M; Donati DM; Fanti S; Nanni C; Benini S; Longhi A; Paioli A; Marrari A; Hakim R; Righi A; Ibrahim T
    Front Oncol; 2023; 13():1252359. PubMed ID: 37876963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
    Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
    Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
    [No Abstract]   [Full Text] [Related]  

  • 8. Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
    Mortensen L; Ordulu Z; Dagogo-Jack I; Bossuyt V; Winters L; Taghian A; Smith BL; Ellisen LW; Kiedrowski LA; Lennerz JK; Bardia A; Spring LM
    Oncologist; 2021 Oct; 26(10):818-824. PubMed ID: 34176200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases.
    Metellus P; Camilla C; Bialecki E; Beaufils N; Vellutini C; Pellegrino E; Tomasini P; Ahluwalia MS; Mansouri A; Nanni I; Ouafik L
    Front Oncol; 2024; 14():1382394. PubMed ID: 39087020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
    Wu WC; Chen MH
    Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Identification of a novel
    Yu QX; Zhao WJ; Wang HY; Zhang L; Qin L; Zhang L; Han JL
    Front Oncol; 2023; 13():1123812. PubMed ID: 37188179
    [No Abstract]   [Full Text] [Related]  

  • 12. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
    Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
    JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
    Kummar S; Lassen UN
    Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostatic adenocarcinoma with novel
    Yeh YA; Yang S; Constantinescu M; Chaudoir C; Tanner A; Henry M; Anderson S; Saldivar JS; Serkin F; Fazili T; Lurie AA; Yu X
    Am J Clin Exp Urol; 2019; 7(5):341-345. PubMed ID: 31763365
    [No Abstract]   [Full Text] [Related]  

  • 16. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
    Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
    Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Pekova B; Sykorova V; Mastnikova K; Vaclavikova E; Moravcova J; Vlcek P; Lastuvka P; Taudy M; Katra R; Bavor P; Kodetova D; Chovanec M; Drozenova J; Astl J; Hrabal P; Vcelak J; Bendlova B
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Life Experience with Entrectinib in Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Solid Tumors: A Multicenter Retrospective Trial.
    Yılmaz F; Yaşar S; Mandel NM; Kaçan T; Özdemir M; Doğu GG; Şengül N; Meydan N; Başal FB; Tolunay PK; Hamamcı MB; Dinçer OS; Bahçeci A; Özer L; Ajredini M; Kırca Ö; Yersal Ö; Can O; Günaldı M; Demir G; Yalçın Ş
    Target Oncol; 2024 Sep; ():. PubMed ID: 39317891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series.
    Yokota T; Yukino H; Doi M; Ohori H
    Head Neck; 2023 May; 45(5):E10-E15. PubMed ID: 36924196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: A case of complete response to entrectinib in
    Moriyama E; Nagasu S; Tanaka T; Shimotsuura Y; Ono T; Umeno H; Akiba J; Kawahara A; Fujita F; Kawaguchi T; Miwa K
    Front Oncol; 2023; 13():1247435. PubMed ID: 37601665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.